A cure for HIV: is it in sight?

References

• UNAIDS (2013) Global Report: UNAIDS report on the global AIDS epidemic. 2013
   Google Scholar
• Chun TW, Finzi D, Margolick J, et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995;1:1284-90
   PubMed Web of Science ®Google Scholar
• Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300
   PubMed Web of Science ®Google Scholar
• Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010;24:2803-8
   PubMed Web of Science ®Google Scholar
• Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res 2008;6:388-400
   PubMed Web of Science ®Google Scholar
• Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010;16:446-51
   PubMed Web of Science ®Google Scholar
• Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-8
   PubMed Web of Science ®Google Scholar
• Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013;9:e1003347
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Hu Z, Li JZ, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013;207:1694-702
   PubMed Web of Science ®Google Scholar
• Henrich T, Hill AL, Goldstein E, et al. Mathematical Modeling of HIV-1 Latent Reservoir Dynamics Following Hematopoietic Stem Cell Transplantation. HIV Persistence during Therapy Sixth International Workshop; Miami, Florida USA; 2013
   Google Scholar
• Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-10
   Google Scholar
• Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010;28:839-47
   PubMed Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823-6
   PubMed Web of Science ®Google Scholar
• Ebina H, Misawa N, Kanemura Y, Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013;3:2510
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Chavez L, Hakre S, et al. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013;21:277-85
   PubMed Web of Science ®Google Scholar
• Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012;487:482-5
   PubMed Web of Science ®Google Scholar
• Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012;36:491-501
   PubMed Web of Science ®Google Scholar
• Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013;381:2109-17
   PubMed Web of Science ®Google Scholar
• Wang FX, Xu Y, Sullivan J, et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 2005;115:128-37
   PubMed Web of Science ®Google Scholar
• Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013;121:4321-9
   PubMed Web of Science ®Google Scholar
• Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010;6:e1000803
   PubMed Web of Science ®Google Scholar
• Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011;6:181-7
   PubMed Web of Science ®Google Scholar
• Hersperger AR, Migueles SA, Betts MR, Connors M. Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 2011;6:169-73
   PubMed Web of Science ®Google Scholar
• Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011;7:e1001300
   PubMed Web of Science ®Google Scholar
• Graf EH, Pace MJ, Peterson BA, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013;8:e71879
   PubMed Web of Science ®Google Scholar
• Hansen SG, Piatak M Jr, Ventura AB, et al. Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100-4
   PubMed Web of Science ®Google Scholar
• Casazza JP, Bowman KA, Adzaku S, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013;207:1829-40
   PubMed Web of Science ®Google Scholar
• Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013;5:166ra162
   Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7
   PubMed Web of Science ®Google Scholar
• Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009;458:206-10
   PubMed Web of Science ®Google Scholar
• Massanella M, Martinez-Picado J, Blanco J. Attacking the HIV reservoir from the immune and viral perspective. Curr HIV/AIDS Rep 2013;10:33-41
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
   PubMed Web of Science ®Google Scholar
• Pallikkuth S, Rogers K, Villinger F, et al. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011;29:9229-38
   PubMed Web of Science ®Google Scholar
• Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer 2011;2:378-82
   PubMed Web of Science ®Google Scholar
• Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012;4:132ra153
   Google Scholar
• Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013;369:1828-35
   PubMed Web of Science ®Google Scholar
• Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012;17:1001-9
   PubMed Web of Science ®Google Scholar
• Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211
   PubMed Web of Science ®Google Scholar
• Investigators ST, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368:207-17
   PubMed Web of Science ®Google Scholar
• Stohr W, Fidler S, McClure M, et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 2013;8:e78287
   PubMed Web of Science ®Google Scholar
• Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191:1410-18
   PubMed Web of Science ®Google Scholar
• Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208:1202-11
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000;97:3382-7
   PubMed Web of Science ®Google Scholar
• Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013;9:e1003174
   PubMed Web of Science ®Google Scholar
• Laird GM, Eisele EE, Rabi SA, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013;9:e1003398
   PubMed Web of Science ®Google Scholar
• Graf EH, O’Doherty U. Quantitation of integrated proviral DNA in viral reservoirs. Curr Opin HIV AIDS 2013;8:100-5
   PubMed Web of Science ®Google Scholar
• Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013;155:540-51
   PubMed Web of Science ®Google Scholar
• Azzoni L, Foulkes AS, Papasavvas E, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 2013;207:213-22
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, Neaton JD, Gordin F, et al. Strategies for Management of Antiretroviral Therapy Study G. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007;21:1957-63
   PubMed Web of Science ®Google Scholar
• Baroncelli S, Galluzzo CM, Andreotti M, et al. HIV-1 coreceptor switch during 2 years of structured treatment interruptions. Eur J Clin Microbiol Infect Dis 2013;32:1565-70
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Airoldi M, Callegaro A, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009;23:799-807
   PubMed Web of Science ®Google Scholar
• Henry K, Katzenstein D, Cherng DW, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102. J Acquir Immune Defic Syndr 2006;42:140-8
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006;368:459-65
   PubMed Web of Science ®Google Scholar
• Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect 2003;79:74
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203
   PubMed Web of Science ®Google Scholar
• Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-90
   PubMed Web of Science ®Google Scholar
• Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009;200:973-83
   PubMed Web of Science ®Google Scholar
• Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009;23:929-39
   PubMed Web of Science ®Google Scholar
• Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 2010;82:1819-28
   PubMed Web of Science ®Google Scholar
• Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012;26:1895-905
   PubMed Web of Science ®Google Scholar
• Safety and effect of the HDAC inhibitor panobinostat on HIV-1 expression in patients on suppressive HAART (CLEAR). Available from: http://clinicaltrials.gov/ct2/show/NCT01680094
   Google Scholar